Tianjin Tianyao Pharmaceuticals Co Ltd (600488) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tianjin Tianyao Pharmaceuticals Co Ltd (600488) has a cash flow conversion efficiency ratio of 0.003x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥13.19 Million ≈ $1.93 Million USD) by net assets (CN¥3.89 Billion ≈ $569.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 600488 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Tianjin Tianyao Pharmaceuticals Co Ltd - Cash Flow Conversion Efficiency Trend (2000–2024)
This chart illustrates how Tianjin Tianyao Pharmaceuticals Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tianjin Tianyao Pharmaceuticals Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tianjin Tianyao Pharmaceuticals Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chongqing Changan Automobile Co Ltd
SHE:200625
|
-0.065x |
|
Nanjing Hongbaoli Corp Ltd
SHE:002165
|
-0.026x |
|
Sichuan Tianyi Comheart Telecom Co Ltd Class A
SHE:300504
|
0.004x |
|
Zhengzhou Coal Industry & Electric Power Co Ltd
SHG:600121
|
-0.007x |
|
Tianjin Jiuri New Materials Co Ltd
SHG:688199
|
0.022x |
|
Esperion Therapeutics Inc
NASDAQ:ESPR
|
0.009x |
|
NioCorp Developments Ltd. Common Stock
NASDAQ:NB
|
-0.010x |
|
Beijing ConST Instruments Technology Inc
SHE:300445
|
0.040x |
Annual Cash Flow Conversion Efficiency for Tianjin Tianyao Pharmaceuticals Co Ltd (2000–2024)
The table below shows the annual cash flow conversion efficiency of Tianjin Tianyao Pharmaceuticals Co Ltd from 2000 to 2024. For the full company profile with market capitalisation and key ratios, see 600488 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥3.89 Billion ≈ $568.62 Million |
CN¥569.37 Million ≈ $83.32 Million |
0.147x | -29.76% |
| 2023-12-31 | CN¥3.75 Billion ≈ $549.23 Million |
CN¥783.01 Million ≈ $114.58 Million |
0.209x | +19.83% |
| 2022-12-31 | CN¥3.75 Billion ≈ $549.30 Million |
CN¥653.52 Million ≈ $95.63 Million |
0.174x | +109.69% |
| 2021-12-31 | CN¥3.82 Billion ≈ $558.53 Million |
CN¥316.89 Million ≈ $46.37 Million |
0.083x | -9.71% |
| 2020-12-31 | CN¥3.77 Billion ≈ $552.05 Million |
CN¥346.88 Million ≈ $50.76 Million |
0.092x | +18.02% |
| 2019-12-31 | CN¥3.59 Billion ≈ $524.74 Million |
CN¥279.37 Million ≈ $40.88 Million |
0.078x | +35.10% |
| 2018-12-31 | CN¥3.28 Billion ≈ $480.28 Million |
CN¥189.27 Million ≈ $27.70 Million |
0.058x | +2315.44% |
| 2017-12-31 | CN¥3.13 Billion ≈ $457.91 Million |
CN¥-8.15 Million ≈ $-1.19 Million |
-0.003x | -110.24% |
| 2016-12-31 | CN¥2.49 Billion ≈ $364.44 Million |
CN¥63.32 Million ≈ $9.27 Million |
0.025x | -51.92% |
| 2015-12-31 | CN¥2.45 Billion ≈ $358.33 Million |
CN¥129.50 Million ≈ $18.95 Million |
0.053x | -29.13% |
| 2014-12-31 | CN¥2.40 Billion ≈ $350.53 Million |
CN¥178.76 Million ≈ $26.16 Million |
0.075x | +105.28% |
| 2013-12-31 | CN¥2.33 Billion ≈ $340.36 Million |
CN¥84.55 Million ≈ $12.37 Million |
0.036x | +385.84% |
| 2012-12-31 | CN¥1.77 Billion ≈ $258.69 Million |
CN¥13.23 Million ≈ $1.94 Million |
0.007x | -83.92% |
| 2011-12-31 | CN¥1.69 Billion ≈ $246.84 Million |
CN¥78.47 Million ≈ $11.48 Million |
0.047x | -35.03% |
| 2010-12-31 | CN¥1.63 Billion ≈ $238.75 Million |
CN¥116.82 Million ≈ $17.09 Million |
0.072x | -74.40% |
| 2009-12-31 | CN¥1.56 Billion ≈ $227.69 Million |
CN¥435.13 Million ≈ $63.67 Million |
0.280x | +91.77% |
| 2008-12-31 | CN¥1.50 Billion ≈ $220.07 Million |
CN¥219.31 Million ≈ $32.09 Million |
0.146x | +31.22% |
| 2007-12-31 | CN¥1.46 Billion ≈ $213.75 Million |
CN¥162.33 Million ≈ $23.75 Million |
0.111x | +136.07% |
| 2006-12-31 | CN¥1.08 Billion ≈ $157.67 Million |
CN¥50.72 Million ≈ $7.42 Million |
0.047x | +145.17% |
| 2005-12-31 | CN¥1.04 Billion ≈ $152.86 Million |
CN¥-108.87 Million ≈ $-15.93 Million |
-0.104x | -193.30% |
| 2004-12-31 | CN¥987.47 Million ≈ $144.50 Million |
CN¥110.30 Million ≈ $16.14 Million |
0.112x | +128.34% |
| 2003-12-31 | CN¥935.65 Million ≈ $136.92 Million |
CN¥45.77 Million ≈ $6.70 Million |
0.049x | -15.24% |
| 2002-12-31 | CN¥784.51 Million ≈ $114.80 Million |
CN¥45.28 Million ≈ $6.63 Million |
0.058x | -42.62% |
| 2001-12-31 | CN¥714.63 Million ≈ $104.57 Million |
CN¥71.87 Million ≈ $10.52 Million |
0.101x | -48.14% |
| 2000-12-31 | CN¥211.75 Million ≈ $30.99 Million |
CN¥41.06 Million ≈ $6.01 Million |
0.194x | -- |
About Tianjin Tianyao Pharmaceuticals Co Ltd
Tianjin Tianyao Pharmaceuticals Co., Ltd. engages in the research and development, production, and sales of corticosteroids, amino acid active pharmaceutical ingredients (APIs), and preparations in China. The company's primary products comprising corticosteroid raw materials, such as dexamethasone, prednisone, methylprednisolone, and betamethasone product series. The company provides amino acid r… Read more